Fig. 1
From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Mean BCVA of patients at the 3-month follow-up was 57.0 ± 17.7 letters, which was significantly increased by 7.3 ± 12.4 letters compared to baseline (p < 0.01). At the 12-month follow-up, the mean BCVA was 53.1 ± 18.0 letters, which was increased by 3.4 ± 15.4 letters compared to baseline, and there was no statistical difference (p > 0.05). Error bars indicate the upper and lower bounds of the 95% CIs. *Significant statistical difference (p < 0.05). **Significant statistical difference (p < 0.01) between groups